Travere Therapeutics (TVTX) Stock Forecast & Price Target

Travere Therapeutics is a biopharmaceutical company that has a positive outlook due to its strong pipeline of rare disease treatments, including its late-stage candidates sparsentan and pegtibatinase. With projected FDA approvals and continued discussions with the US Patent and Trademark Office, the company has a promising outlook for its existing and future exclusivity. While there are potential risks such as dilution of stock and delays in commercialization, the company has a strong cash balance and a solid plan for execution upon approval. The recent FDA approval of Filspari for the treatment of FSGS is a major milestone for the company, and with potential M&A opportunities and a lower valuation discount rate, we anticipate a successful launch and significant growth for Travere Therapeutics in the near future.

Travere Therapeutics is facing a potential risk due to potential delays in the launch of their new drug, Filspari, as it has faced a postponement in the FDA decision date. Additionally, there may be limitations on the use of the drug in patients with active Nephrotic Syndrome, which could impact the company's projected future revenues. In order to advance their portfolio and support commercialization efforts, Travere may need to access the capital markets, which could be limited by potential funding constraints and failed clinical trials, impeding their ability to reach their projected price target.